The All-Index
E271May 1, 2026

OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze

Takes
11
Companies
7
Right so far
1
Wrong so far
3

Directional takes judged by each stock's move since this episode aired.

GoogleGOOGL-6.6% since this episode
FriedbergFriedbergBullish✗ wrong so far

Friedberg highlights Google's strong position in both consumer and enterprise AI markets — with Gemini neck-and-neck with ChatGPT in consumer and 75% of GCP customers using Vertex — as the likely reason the stock has ripped recently.

This is also probably why Google stock has absolutely ripped over the last couple of months is they're literally in first place or fighting for first place in enterprise and consumer.
JasonJasonBullish✗ wrong so far

Jason argues Google has successfully balanced AI-powered search with advertising revenue, with search revenue surging alongside Gemini user growth, vindicating the strategy of integrating AI at the top of search results.

Search revenue is surging and they're also surging. So they figured out a way to balance those two competing forces, having search results that are AI-enabled and still getting people to click on links. They've done it brilliantly,
SacksSacksBullish✗ wrong so far

Sacks argues Google has brilliantly recaptured consumer AI market share through Gemini integration into Search, effectively neutralizing OpenAI's consumer lead and validating its long-term competitive position.

If there is a single reason why OpenAI did not hit its user targets... you'd have to say it's because Google managed to take meaningful share. They were basically nowhere a year or so ago... they did a brilliant job improving Gemini and
ChamathChamathBullish

Chamath views Anthropic as a multi-trillion-dollar company whose near-term misses are purely supply-constrained, and believes it should strike a compute deal with Elon/Grok immediately to unlock its demand potential.

I think Anthropic is a multi-trillion-dollar company... he and Dario should do a deal tomorrow.
SacksSacksMixed

Sacks sees Anthropic as compute-constrained and losing developer momentum to OpenAI's GPT-5.5, with Opus 4.7 underperforming and token rationing hurting its ability to serve customers, though he views these as prudent business decisions rather than structural failures.

Anthropic is token constrained. It's reducing their ability to serve Mythos, for example. It's causing them to engage in compute gating with Opus 4.7.
ChamathChamathBullish

Chamath believes OpenAI is a multi-trillion-dollar company and that its missed targets are entirely a supply-side power/compute constraint, not a demand problem, making the business fundamentally sound long-term.

I think they're going to be fine. I think this is a multi-trillion-dollar company... To the extent that OpenAI missed, I think what that is is an insight to not enough compute capacity today.
SacksSacksMixed

Sacks is cautiously bullish on OpenAI's competitive position despite missing consumer targets, arguing that GPT-5.5's strong product reception, a new base model, and superior compute capacity versus token-constrained Anthropic position OpenAI to dominate the all-important enterprise coding market.

I think Sam may end up being right here for the wrong reason, which is he missed on consumer, but enterprise is going gangbusters and is giving him the ability now, I think, to catch up on consumer.
MicrosoftMSFT-3.7% since this episode
ChamathChamathMixed

Chamath is cautious on Microsoft's long-term valuation as its massive AI CapEx commitments — including energy forward contracts at 2x spot rate — shift it toward a leveraged, asset-heavy industrial profile that may not support current equity valuations.

When Microsoft convinced the owners of Three Mile Island to turn their Nuclear Site Back On... their forward purchase agreement was for more than 2x the prevailing spot rate for energy... These companies will now get levered.
Eli LillyLLY+19.1% since this episode
FriedbergFriedbergBullish✓ right so far

Friedberg is bullish on Lilly's retatrutide pipeline as a transformative premium product — with Phase 3 data showing superior fat loss, muscle preservation, and systemic health benefits — that positions Lilly to command high pricing as the clear upgrade from tirzepatide.

If I'm Lilly and I'm sitting there and I'm looking at this data coming out, I'm like, my God, people will pay for this. And that starts to become sort of like the upgrade to the BMW, or the Model S Plaid, if you will.
AmazonAMZN-10.0% since this episode
ChamathChamathMixed

Chamath argues the hyperscalers including Amazon are shifting from asset-light free-cash-flow machines to highly leveraged industrial businesses due to massive AI CapEx and above-market energy costs, raising doubts about long-term valuation while acknowledging near-term cloud demand strength.

They're going to look like this big bulky industrial business in 5 years. And I'm not sure that there's a good valuation case to be made at that point.
SacksSacksBullish

Sacks argues that the hyperscalers' blowout cloud earnings and accelerating CapEx validate the bull thesis for AI broadly, with voracious enterprise demand for compute ensuring no 'dark GPU' scenario analogous to the dot-com dark fiber bust.

The bull thesis for AI just got validated in a single afternoon... There's no dark GPUs today... what's driving the CapEx now is the voracious demand for compute, for tokens, and the demand is now pulling forward this additional investment